Discontinuation of Genetic Testing for Chronic Idiopathic Pancreatitis
30 May 2025
Following a recent review, PathWest will discontinue genetic testing for chronic idiopathic pancreatitis (CIP) from 03 June 2025.
This decision follows a clinical and operational review which identified:
CIP testing is not supported by Medicare.
Current CIP testing has limited clinical utility in comparison to the international benchmark: Low
diagnostic yield of less than 10% compared to 20 to 30% (PMID: 39172977).
Broader and more comprehensive hereditary pancreatitis testing is available internationally through
other providers. These include:
Canterbury Health Laboratories (NZ) – PRSS1, SPINK1, CFTR, CELA3B
ARUP Laboratories (USA) – CFTR, CTRC, PRSS1, SPINK1
Prevention Genetics (USA) – CASR, CFTR, CPA1, CTRC, PRSS1, SPINK1, TRPV6
Blueprint Genetics (USA) – APOA5, APOC2, CFTR, CPA1, CTRC, GPIHBP1, PRSS1, SPINK1, UBR1
We ap...